2,5-Dimethoxyamphetamine-derived designer drugs: Studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6

Toxicology Letters

Volumn 183, Issue 1-3, 2008, Pages 52-57

  Ewald, Andreas H ^a   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

CYP2D6; Cytochrome P450; Designer drugs; Inhibition; Ki

Indexed keywords

2,4,5 TRIMETHOXYAMPHETAMINE; 2,5 DIMETHOXY 4 BROMOMETHAMPHETAMINE; 2,5 DIMETHOXY 4 METHYLAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 CHLORO 2,5 DIMETHOXYAMPHETAMINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; AMPHETAMINE DERIVATIVE; BROLAMFETAMINE; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; FLUOXETINE; O DEMETHYLASE; QUINIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; INSECT CELL; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

2,5-DIMETHOXY-4-METHYLAMPHETAMINE; ALGORITHMS; AMPHETAMINES; ANIMALS; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DESIGNER DRUGS; FLUOXETINE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; HYDROXYLATION; INSECTS; KINETICS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; QUINIDINE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

HEXAPODA;

EID: 56549131437     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.09.014     Document Type: Article

References (28)

1. Balikova M. Nonfatal and fatal DOB (2,5-dimethoxy-4-bromoamphetamine) overdose. Forensic Sci. Int. 153 (2005) 85-91
2. Cornish-Bowden A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochem. J. 137 (1974) 143-144
3. Correia M.A., and Ortiz-de-Montellano P.R. Inhibition of cytochrome P450 enzymes. In: Ortiz-de-Montellano P.R. (Ed). Cytochrome P450-Structure, Mechanism, and Biochemistry. 3rd ed. (2005), Kluwer Academic/Plenum Publishers, New York 247-322
4. de la Torre R., Farre M., Mathuna B.O., Roset P.N., Pizarro N., Segura M., Torrens M., Ortuno J., Pujadas M., and Cami J. MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur. J. Clin. Pharmacol. 61 (2005) 551-554
5. Drug Enforcement Administration-Office of Forensic Sciences, 2006. Intelligence alert large fentanyl/MDA/TMA laboratory in Azuza, California-possibly the "OC-80" tablet source. Microgram 39, 45-47.
6. Drug Enforcement Administration-Office of Forensic Sciences, 2006. Intelligence alert: 4-chloro-2,5-dimethoxyamphetamine (DOC) and 4-iodo-2,5-dimethoxyamphetamine (DOI) in Berkley, Michigan. Microgram 39, 137.
7. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2003. Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs. http://www.emcdda.europa. eu/attachements.cfm/att_33358_EN_Risk7.pdf. Accessed August 5, 2008.
8. Evans W.E., and McLeod H.L. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348 (2003) 538-549
9. Ewald A.H., Ehlers D., and Maurer H.H. Metabolism and toxicological detection of the designer drug 4-chloro-2,5-dimethoxyamphetamine in rat urine using gas chromatography-mass spectrometry. Anal. Bioanal. Chem. 390 (2008) 1837-1842
10. Ewald A.H., Fritschi G., Bork W.R., and Maurer H.H. Designer drugs 2,5-dimethoxy-4-bromoamphetamine (DOB) and 2,5-dimethoxy-4-bromomethamphetamine (MDOB): Studies on their metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 41 (2006) 487-498
11. Ewald A.H., Fritschi G., and Maurer H.H. Designer drug 2,4,5-trimethoxyamphetamine (TMA-2): Studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques. J. Mass Spectrom. 41 (2006) 1140-1148
12. Ewald A.H., Fritschi G., and Maurer H.H. Metabolism and toxicological detection of the designer drug 4-iodo-2,5-dimethoxy-amphetamine (DOI) in rat urine using gas chromatography-mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 857 (2007) 170-174
13. Ewald A.H., Puetz M., and Maurer H.H. Designer drug 2,5-dimethoxy-4-methyl-amphetamine (DOM, STP): involvement of the cytochrome P450 isoenzymes in formation of its main metabolite and detection of the latter in rat urine as proof of a drug intake using gas chromatography-mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 862 (2008) 252-256
14. Heydari A., Yeo K.R., Lennard M.S., Ellis S.W., Tucker G.T., and Rostami-Hodjegan A. Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamine. Drug Metab. Dispos. 32 (2004) 1213-1217
15. Ho B.T., Estevez V., Tansey L.W., Englert L.F., Creaven P.J., and McIsaac W.M. Analogs of amphetamine. 5. Studies of excretory metabolites of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) in rats. J. Med. Chem. 14 (1971) 158-160
16. i in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug Metab. Dispos. 27 (1999) 756-762
17. Krishnan S., and Moncrief S. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab. Dispos. 35 (2007) 180-184
18. Monte A.P., Marona-Lewicka D., Parker M.A., Wainscott D.B., Nelson D.L., and Nichols D.E. Dihydrobenzofuran analogues of hallucinogens. 3. Models of 4-substituted (2,5-dimethoxyphenyl)alkylamine derivatives with rigidified methoxy groups. J. Med. Chem. 39 (1996) 2953-2961
19. Neuvonen K., Neuvonen H., and Fulop F. Effect of 4-substitution on psychotomimetic activity of 2,5-dimethoxy amphetamines as studied by means of different substituent parameter scales. Bioorg. Med. Chem. Lett. 16 (2006) 3495-3498
20. Otton S.V., Wu D., Joffe R.T., Cheung S.W., and Sellers E.M. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin. Pharmacol. Ther. 53 (1993) 401-409
21. Pritzker D., Kanungo A., Kilicarslan T., Tyndale R.F., and Sellers E.M. Designer drugs that are potent inhibitors of CYP2D6. J. Clin. Psychopharmacol. 22 (2002) 330-332
22. Ramamoorthy Y., Yu A.M., Suh N., Haining R.L., Tyndale R.F., and Sellers E.M. Reduced(±)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochem. Pharmacol. 63 (2002) 2111-2119
23. Shen H., He M.M., Liu H., Wrighton S.A., Wang L., Guo B., and Li C. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos. 35 (2007) 1292-1300
24. Shulgin A. Pihkal, A Chemical Love Story. 1st ed. (1991), Transform Press, Berkley (CA)
25. Tucker G.T., Lennard M.S., Ellis S.W., Woods H.F., Cho A.K., Lin L.Y., Hiratsuka A., Schmitz D.A., and Chu T.Y. The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). Biochem. Pharmacol. 47 (1994) 1151-1156
26. Walsky R.L., and Obach R.S. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. 32 (2004) 647-660
27. Wu D., Otton S.V., Inaba T., Kalow W., and Sellers E.M. Interactions of amphetamine analogs with human liver CYP2D6. Biochem. Pharmacol. 53 (1997) 1605-1612
28. Yang J., Jamei M., Heydari A., Yeo K.R., de la Torre R., Farre M., Tucker G.T., and Rostami-Hodjegan A. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J. Psychopharmacol. 20 (2006) 842-849